Eosinophilic Gastrointestinal Diseases (EGIDs) and Lung Health: Understanding Respiratory Symptoms and Risks Eosinophilic Gastrointestinal Diseases (EGIDs) and the Lungs Eosinophilic Gastrointestinal Diseases (EGIDs) are chronic conditions caused by high levels of eosinophils in the digestive tract, leading to inflammation and digestive symptoms such as abdominal pain, vomiting, and difficulty swallowing. Research increasingly shows a strong gut–lung connection, with many people with EGIDs also experiencing respiratory symptoms like asthma, wheezing, or chronic cough. Around 5% asthma patients have severe (eosinophilic) asthma. Understanding the link between EGIDs and lung health is essential for early diagnosis, comprehensive care, and improving quality of life for patients affected by these complex type 2 inflammatory diseases. Watch the Webinar: EGIDs and the Lungs Presented by: Pujan Patel, Consultant in Respiratory Medicine at the Royal Brompton Hospital, London and Honorary Senior Clinical Lecturer at Imperial College London Explore the connection between Eosinophilic Gastrointestinal Diseases (EGIDs) and type 2 inflammatory respiratory conditions, including eosinophilic asthma, general asthma, chronic rhinitis, and other multi-system diseases. Help us to develop more resources like this Key Topics Covered: What are eosinophilic diseases Understanding an overlap between EGIDs and lung conditions Eosinophilic Oesophagitis (EoE) and asthma What is asthma? Common symptoms Challenges of diagnosing asthma: typical symptoms and diagnostic tools Peak Flow Variability meter Lung function testing Fractional Exhaled Nitric Oxide (FENO) Common asthma mimics Sputum eosinophil-guided asthma therapy: study results Risk of asthma exacerbation and blood eosinophil count FENO levels and asthma exacerbations risk Asthma diagnosis, treatment & management guidelines Severe asthma patients and healthcare costs for uncontrolled eosinophilic asthma Harms of cumulative oral corticosteroid (OCS) exposure: study results Biologic therapies: omalizumab, dupilumab and others Real-world impact of the biologic treatments Asthma services structure (the UK) Eosinophilic Granulomatosis with Polyangitis (EGPA), previously Churg-Strauss Syndrome (CSS): clinical manifestations, diagnosis and management The gut-lung axis Additional Resources What is Eosinophil? Understanding Clinical Trials Biologics for Eosinophilic Diseases: Latest News & Research Burden of Oral Corticosteroids in Severe Asthma: Key Takeaways from a 2025 Review Eosinophilic Oesophagitis and Asthma: A Revealing Connection in Hospital Visits Benralizumab for Eosinophilic Asthma and COPD Exacerbations. ABRA Study Findings Persistent Asthma Symptoms in Children on Mepolizumab This resource was developed with support from the National Lottery Community Fund. Manage Cookie Preferences